Myelodysplastic Syndromes (MDS)

Very long-term remission with azacitidine in VEXAS syndrome

Original Publication Date
Article Source
External Web Content
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly identified monogenic disorder with symptoms including recurrent fever, skin involvement, pulmonary infiltrates, systemic vasculitis, and chondritis. 1 Notably, 25-50% of patients also have…

Nutrition for Patients with Aplastic Anemia, MDS, or PNH

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Living Well with Bone Marrow Failure
Myelodysplastic Syndromes (MDS)
In this webinar, Kylie Chen, Registered Dietitian, discusses common nutrition challenges and evidence-based strategies to improve nutritional status and learn easy nutrition swaps.

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

Allogeneic hematopoietic stem-cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher-risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and molecular heterogeneity, necessitating personalized approaches to patient selection, timing, and transplant management. For MDS, genomic profiling has revolutionized prognostic frameworks such as IPSS-M, enabling tailored therapeutic decisions.

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.